August 24, 2026 ImmunoForge Selected for the Ministry of SMEs and Startups’ ‘Global TIPS R&D’ Program… “Expansion of the LMT Platform”
August 24, 2026 ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1